Pacira BioSciences, Inc.

NASDAQ:PCRX

Drug Manufacturers - Specialty & Generic

Healthcare
$36.48 -0.79%

-$0.18 today

Market cap
$1.46B
Beta
0.29
P/E (TTM)
176.9
EPS (TTM)
$0.13
52W Low $18.80High $27.64

Volume 1.81M

Average 0.57M

PCRX EBITDA Margin

EBITDA as a percentage of revenue.

Pacira BioSciences, Inc.NASDAQ: PCRX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 16.6%

EBITDA Margin was 16.6% in Q1 FY2026, down 3.3 pp from a year earlier. On a trailing-twelve-month basis it was 16.1%, up 12.1 pp year over year. Over 3 fiscal years it narrowed by 4.2 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 35.6% for the fiscal year ending Dec 2026, up from 16.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
16.6%+3.8 pp QoQ
Last fiscal yearDec 2025
16.9%+12.7 pp YoY
LTMMar 2026
16.1%+12.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.3 pp+14.9 pp+18.1 pp
1 year+12.7 pp+18.8 pp+6.0 pp
3 years-4.2 pp+23.3 pp+27.5 pp
5 years+21.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
16.9%
Year-over-year change
+12.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PCRX compares with its peers on the latest reported figures

  • PCRX's LTM Mar 2026 EBITDA Margin of 16.1% is the 2nd highest of the 4 companies compared; the peer median is -1.9%.
  • Its year-over-year change of +12.1 pp is the 2nd highest of 4, against a peer median of -26.9 pp.
  • Over three fiscal years its change of -4.2 pp compares with a peer median of -17.1 pp.
PCRX Competitors Peer median
EBITDA Margin for PCRX and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
PCRXPacira BioSciences, Inc.LTM Mar 202616.1% +12.1 pp-4.2 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
SCLXScilex Holding CompanyLTM Mar 2026-1105.5% -974.2 pp-1158.7 pp
LTGOLatigo Biotherapeutics Inc.—— ——
Peer median (excluding PCRX) -1.9%-26.9 pp-17.1 pp

Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue541.53M666.82M674.98M700.97M726.41M
Cost of Revenue140.26M199.3M184.67M170.43M149.75M
Gross Profit401.28M467.53M490.31M530.54M576.66M
Gross Margin74.1%70.1%72.6%75.7%79.4%
Research & Development55.55M84.8M76.26M81.58M117.31M
Selling, General & Admin199.35M254.52M269.44M294.1M368.76M
Operating Expenses311.35M407.5M402.63M603.91M543.36M
Depreciation & Amortization28.55M91.5M75.57M78.79M91.02M
EBITDA113.95M140.38M154.59M29.12M122.5M
EBITDA Margin21.0%21.1%22.9%4.2%16.9%
Operating Income89.92M60.02M87.68M(73.37M)33.3M
Operating Margin16.6%9.0%13.0%-10.5%4.6%
Interest Income896K4.54M11.44M19.69M22.73M
Interest Expense29M35.58M17.31M16.57M14.61M
Other Income / Expenses(33.52M)(46.72M)(25.97M)10.27M(16.43M)
Income Before Tax56.4M13.3M61.7M(63.11M)16.87M
Pre-Tax Margin10.4%2.0%9.1%-9.0%2.3%
Income Tax Expense14.42M(2.61M)19.75M36.45M9.84M
Net Income41.98M15.91M41.96M(99.56M)7.03M
Net Margin7.8%2.4%6.2%-14.2%1.0%
EPS (Basic)0.950.350.91(2.15)0.16
EPS (Diluted)0.920.340.89(2.15)0.16
Weighted Avg Shares44.26M45.52M46.22M46.25M44.57M
Weighted Avg Shares (Diluted)45.63M46.54M51.98M46.25M45.04M

Pacira BioSciences, Inc.

NASDAQ:PCRX

Intrinsic Alpha fair value

Locked

Current Price

$36.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.